Most Read
Most Commented
Read more like this
mk-logo
From Our Readers
Cancer treatment drugs continue to be made available for ministry patients

With reference to the article published in The Malay Mail Online on Dec 5, 2016 titled ‘Why New Cancer Drugs Are Unavailable in Malaysian Public Hospitals’, the Health Ministry would like to clarify some misunderstandings highlighted in this article.

As in most other countries, the ministry has a standard formulary for medications, informally known as ‘the Blue Book’, consisting of list of medicines that serve as a guide for doctors with regard to medicines that can be prescribed for patients seeking treatment in Health Ministry facilities.

All medicines listed in the formulary are provided to patients without any charges - patients only pay a mere RM1 to RM5 when seeking outpatient treatment; and for inpatient services, they only pay for ward charges and certain investigations while medicines are provided for free. There is hardly any other country in the world where patients, including those requiring treatment for cancers, can get such access to such services.

Sunitinib, the drug which is being referred to in the MalayMail article, has already been listed in the ministry’s formulary. Prior to being listed in the formulary, the government had already spent approximately RM420,000 to treat 11 patients who required Sunitinib. In 2015, the ministry spent RM240 million just on cancer therapy and this amounted to 10 percent of the total drug budget.

For a medicine to be listed in the Blue Book, it must first be registered in the country. The company responsible for marketing the product shall apply for it to be listed in the formulary. It will then be evaluated based on criteria such as proof of superior effectiveness compared to standard therapy, a positive cost benefit ratio and an acceptable safety profile.

However, not all medicines get listed into the formulary if there is a very high budget impact, especially the newer targeted cancer therapies. Nevertheless, any patient requiring these therapies are never deprived of access to these medicines as the Health Ministry still approves the use of non-formulary medicines on case-to-case basis.

Furthermore, other targeted therapies for lung, liver and renal cancers, gastrointestinal stromal tumours, hematological conditions are among cancer treatment that are already listed in the formulary; although they are very costly. Mostly are available in tertiary Health Ministry hospitals as these conditions require specialised care.

As the new targeted therapies for cancer are very expensive, the ministry has already engaged with the pharmaceutical industry through Patient Access Schemes and Patient Assisted Programmes. These are among measures taken in making these medicines more affordable for he Health Ministry thus enabling a greater number of patients to receive these treatments. Therefore, the ministry will continue to strive in providing the best possible care for our patients through the optimal use of medicines.


DR NOOR HISHAM ABDULLAH is director-general of Health Malaysia.

ADS